Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).
dc.contributor.author | Jacob, S | |
dc.contributor.author | Dunn, B.L | |
dc.contributor.author | Qureshi, Z.P | |
dc.contributor.author | Bandarenko, N | |
dc.contributor.author | Kwaan, H.C | |
dc.contributor.author | Pandey, D.K | |
dc.contributor.author | McKoy, J.M | |
dc.contributor.author | Barnato, S.E | |
dc.contributor.author | Winters, J.L | |
dc.contributor.author | Cursio, J.F | |
dc.contributor.author | Weiss, I | |
dc.contributor.author | Raife, T.J | |
dc.contributor.author | Carey, P.M | |
dc.contributor.author | Sarode, R | |
dc.contributor.author | Kiss, J.E | |
dc.contributor.author | Danielson, C | |
dc.contributor.author | Ortel, T.L | |
dc.contributor.author | Clark, W.F | |
dc.contributor.author | Rock, G | |
dc.contributor.author | Matsumoto, M | |
dc.contributor.author | Fujimura, Y | |
dc.contributor.author | Zheng, X.L | |
dc.contributor.author | Chen, H | |
dc.contributor.author | Chen, F | |
dc.contributor.author | Armstrong, J.M | |
dc.contributor.author | Raisch, D.W | |
dc.contributor.author | Bennett, C.L | |
dc.date.accessioned | 2013-04-26T08:22:30Z | |
dc.date.available | 2013-04-26T08:22:30Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Semin Thromb Hemost. 2012 Nov;38(8):845-53. doi: 10.1055/s-0032-1328894. Epub 2012 Oct 30. | en |
dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/23111862 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16963 | |
dc.description.abstract | Thienopyridine-derivatives (ticlopidine, clopidogrel, and prasugrel) are the primary antiplatelet agents. Thrombotic thrombocytopenic purpura (TTP) is a rare drug-associated syndrome, with the thienopyridines being the most common drugs implicated in this syndrome. We reviewed 20 years of information on clinical, epidemiologic, and laboratory findings for thienopyridine-associated TTP. Four, 11, and 11 cases of thienopyridine-associated TTP were reported in the first year of marketing of ticlopidine (1989), clopidogrel (1998), and prasugrel (2010), respectively. As of 2011, the FDA received reports of 97 ticlopidine-, 197 clopidogrel-, and 14 prasugrel-associated TTP cases. Severe deficiency of ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) was present in 80% and antibodies to 100% of these TTP patients on ticlopidine, 0% of the patients with clopidogrel-associated TTP (p < 0.05), and an unknown percentage of patients with prasugrel-associated TTP. TTP is associated with use of each of the three thienopyridines, although the mechanistic pathways may differ. | en |
dc.language.iso | en | en |
dc.title | Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). | en |
dc.type | Article | en |
Files in this item
This item appears in the following Collection(s)
-
Faculty of Health Sciences (FHS) [10378]